Literature DB >> 11751108

In vitro microbicidal activities of cecropin peptides D2A21 and D4E1 and gel formulations containing 0.1 to 2% D2A21 against Chlamydia trachomatis.

L M Ballweber1, J E Jaynes, W E Stamm, M F Lampe.   

Abstract

Topically applied microbicides that eradicate pathogens at the time of initial exposure represent a powerful strategy for the prevention of sexually transmitted infections. To aid in the further development of an effective topical microbicide, we assessed the minimum cidal concentration (MCC) of two cecropin peptides, D2A21 and D4E1, and gel formulations containing 0.1 to 2% D2A21 against Chlamydia trachomatis in vitro. The MCC of peptide D2A21 was 5 microM (18.32 microg/ml), and that of peptide D4E1 was 7.5 microM (21.69 microg/ml). The MCC of gel formulations containing 2% D2A21 was 0.2 mM (0.7 mg/ml), and that of gel formulations containing 0.5% D2A21 was 0.2 mM (0.7 mg/ml). There was no significant variation in the results when two different C. trachomatis strains were tested, and the addition of 10% human blood did not significantly alter the MCCs. pH values above and below 7 reduced the activity of the D2A21 peptide alone, but the MCC of the 2% D2A21 gel formulation was only slightly altered at the various pHs tested. Ultrastructural studies indicated that C. trachomatis membranes were disrupted after D2A21 exposure, resulting in leakage of the cytoplasmic contents. These in vitro results suggest that these cecropin peptides may be an effective topical microbicide against C. trachomatis and support the need for further evaluation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751108      PMCID: PMC126975          DOI: 10.1128/AAC.46.1.34-41.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  ABC of colorectal diseases. Sexually transmitted diseases and anal papillomas.

Authors:  D J Jones; B P Goorney
Journal:  BMJ       Date:  1992-10-03

Review 2.  Sexually transmitted diseases of the colon, rectum, and anus. The challenge of the nineties.

Authors:  S D Wexner
Journal:  Dis Colon Rectum       Date:  1990-12       Impact factor: 4.585

Review 3.  Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus.

Authors:  S M El-Attar; D V Evans
Journal:  Prim Care       Date:  1999-03       Impact factor: 2.907

4.  Priorities for vaginal microbicide research.

Authors:  D C Sokal; P L Hermonat
Journal:  Am J Public Health       Date:  1995-05       Impact factor: 9.308

5.  Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens.

Authors:  B C Herold; A Siston; J Bremer; R Kirkpatrick; G Wilbanks; P Fugedi; C Peto; M Cooper
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man.

Authors:  N I McNeil; K L Ling; J Wager
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

7.  Clinical manifestations of genital infection due to Chlamydia trachomatis in women: differences related to serovar.

Authors:  K A Workowski; C E Stevens; R J Suchland; K K Holmes; D A Eschenbach; M B Pettinger; W E Stamm
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

8.  Susceptibility of Chlamydia trachomatis to protegrins and defensins.

Authors:  B Yasin; S S Harwig; R I Lehrer; E A Wagar
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

9.  In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria.

Authors:  A Giacometti; O Cirioni; G Greganti; M Quarta; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Susceptibility of Chlamydia trachomatis to chlorhexidine gluconate gel.

Authors:  M F Lampe; L M Ballweber; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  10 in total

1.  Susceptibility of Chlamydia trachomatis to excipients commonly used in topical microbicide formulations.

Authors:  M F Lampe; L C Rohan; M C Skinner; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  LHRH-conjugated lytic peptides directly target prostate cancer cells.

Authors:  Clayton Yates; Starlette Sharp; Jacqueline Jones; Daphne Topps; Mathew Coleman; Ritu Aneja; Jesse Jaynes; Timothy Turner
Journal:  Biochem Pharmacol       Date:  2010-09-30       Impact factor: 5.858

3.  Biosynthesized tea polyphenols inactivate Chlamydia trachomatis in vitro.

Authors:  Tsutomu Yamazaki; Toshio Kishimoto; Sadashi Shiga; Kozue Sato; Toshikatsu Hagiwara; Miyuki Inoue; Nozomu Sasaki; Kazunobu Ouchi; Yukihiko Hara
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis.

Authors:  M C Skinner; A O Kiselev; C E Isaacs; T A Mietzner; R C Montelaro; M F Lampe
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

5.  The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis.

Authors:  Narae Park; Kinrin Yamanaka; Dat Tran; Pete Chandrangsu; Johnny C Akers; Jessica C de Leon; Naomi S Morrissette; Michael E Selsted; Ming Tan
Journal:  J Antimicrob Chemother       Date:  2008-10-27       Impact factor: 5.790

6.  Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing.

Authors:  M C Skinner; W E Stamm; M L Lampe
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

7.  Inhibition of chlamydial infection in the genital tract of female mice by topical application of a peptide deformylase inhibitor.

Authors:  Amit Balakrishnan; Lingling Wang; Xiaojin Li; Pamela Ohman-Strickland; Paul Malatesta; Huizhou Fan
Journal:  Microbiol Res       Date:  2007-10-23       Impact factor: 5.415

Review 8.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

Review 9.  Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides.

Authors:  Nongnuj Tanphaichitr; Nopparat Srakaew; Rhea Alonzi; Wongsakorn Kiattiburut; Kessiri Kongmanas; Ruina Zhi; Weihua Li; Mark Baker; Guanshun Wang; Duane Hickling
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-11

Review 10.  Natural Products for the Treatment of Chlamydiaceae Infections.

Authors:  Mika A Brown; Michael G Potroz; Seoh-Wei Teh; Nam-Joon Cho
Journal:  Microorganisms       Date:  2016-10-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.